P052 Real-life experience with a generic formulation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and responsive CFTR variants with previous modulators therapy.

Autor: Zaragoza, S.1 (AUTHOR), Lubovich, S.1 (AUTHOR), Rodriguez, V.1 (AUTHOR), Rodriguez Novoa, E.1 (AUTHOR), Bracamonte, F.1 (AUTHOR), Ray, L.1 (AUTHOR), Frías, G.1 (AUTHOR), García Bournissen, F.2 (AUTHOR), Teper, A.1 (AUTHOR)
Zdroj: Journal of Cystic Fibrosis. 2024 Supplement 1, Vol. 23, pS82-S82. 1p.
Databáze: Academic Search Ultimate
Externí odkaz: